Khalid Iqbal

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6066539/publications.pdf

Version: 2024-02-01

186 papers	23,814 citations	6254 80 h-index	7950 149 g-index
192 all docs	192 docs citations	192 times ranked	19283 citing authors

#	Article	IF	Citations
1	Defeating Alzheimer's disease and other dementias: a priority for European science and society. Lancet Neurology, The, 2016, 15, 455-532.	10.2	1,242
2	Tau in Alzheimer Disease and Related Tauopathies. Current Alzheimer Research, 2010, 7, 656-664.	1.4	822
3	Tau pathology in Alzheimer disease and other tauopathies. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2005, 1739, 198-210.	3.8	786
4	Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nature Medicine, 1996, 2, 783-787.	30.7	768
5	Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. European Journal of Neuroscience, 2005, 22, 1942-1950.	2.6	657
6	O-GlcNAcylation regulates phosphorylation of tau: A mechanism involved in Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 10804-10809.	7.1	650
7	Tau and neurodegenerative disease: the story so far. Nature Reviews Neurology, 2016, 12, 15-27.	10.1	603
8	Mechanisms of tau-induced neurodegeneration. Acta Neuropathologica, 2009, 118, 53-69.	7.7	577
9	Phosphoprotein Phosphatase Activities in Alzheimer Disease Brain. Journal of Neurochemistry, 1993, 61, 921-927.	3.9	489
10	Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. European Journal of Neuroscience, 2007, 25, 59-68.	2.6	461
11	DEFECTIVE BRAIN MICROTUBULE ASSEMBLY IN ALZHEIMER'S DISEASE. Lancet, The, 1986, 328, 421-426.	13.7	450
12	Distribution of Active Glycogen Synthase Kinase 3Î² (GSK-3Î²) in Brains Staged for Alzheimer Disease Neurofibrillary Changes. Journal of Neuropathology and Experimental Neurology, 1999, 58, 1010-1019.	1.7	429
13	Occurrence of neuropil threads in the senile human brain and in Alzheimer's disease: A third location of paired helical filaments outside of neurofibrillary tangles and neuritic plaques. Neuroscience Letters, 1986, 65, 351-355.	2.1	413
14	Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes. Journal of Pathology, 2011, 225, 54-62.	4.5	401
15	Phosphatase Activity Toward Abnormally Phosphorylated Ï„: Decrease in Alzheimer Disease Brain. Journal of Neurochemistry, 1995, 65, 732-738.	3.9	398
16	Phosphorylation of Microtubule-associated Protein Tau Is Regulated by Protein Phosphatase 2A in Mammalian Brain. Journal of Biological Chemistry, 2000, 275, 5535-5544.	3.4	374
17	Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease. Brain, 2009, 132, 1820-1832.	7.6	350
18	CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimer's and Dementia, 2013, 9, 251-261.	0.8	344

#	Article	IF	Citations
19	Abnormal Hyperphosphorylation of Tau: Sites, Regulation, and Molecular Mechanism of Neurofibrillary Degeneration. Journal of Alzheimer's Disease, 2012, 33, S123-S139.	2.6	318
20	Distribution, Levels, and Activity of Glycogen Synthase Kinase-3 in the Alzheimer Disease Brain. Journal of Neuropathology and Experimental Neurology, 1997, 56, 70-78.	1.7	316
21	Glycosylation of microtubuleâ€“associated protein tau: An abnormal posttranslational modification in Alzheimer's disease. Nature Medicine, 1996, 2, 871-875.	30.7	310
22	Brain Levels of Microtubule-Associated Protein ? Are Elevated in Alzheimer's Disease: A Radioimmuno-Slot-Blot Assay for Nanograms of the Protein. Journal of Neurochemistry, 1992, 59, 750-753.	3.9	298
23	Up-Regulation of Phosphorylated/Activated p70 S6 Kinase and Its Relationship to Neurofibrillary Pathology in Alzheimer's Disease. American Journal of Pathology, 2003, 163, 591-607.	3.8	294
24	Promotion of Hyperphosphorylation by Frontotemporal Dementia Tau Mutations. Journal of Biological Chemistry, 2004, 279, 34873-34881.	3.4	251
25	Dephosphorylation of Alzheimer Paired Helical Filaments by Protein Phosphatase-2A and â^'2B. Journal of Biological Chemistry, 1995, 270, 4854-4860.	3.4	238
26	A Non-transgenic Mouse Model (icv-STZ Mouse) of Alzheimerâ€™s Disease: Similarities to and Differences from the Transgenic Model (3xTg-AD Mouse). Molecular Neurobiology, 2013, 47, 711-725.	4.0	226
27	Accumulation of cyclin-dependent kinase 5 (cdk5) in neurons with early stages of Alzheimer's disease neurofibrillary degeneration. Brain Research, 1998, 797, 267-277.	2.2	220
28	Failure of Neuronal Maturation in Alzheimer Disease Dentate Gyrus. Journal of Neuropathology and Experimental Neurology, 2008, 67, 78-84.	1.7	212
29	Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome. FASEB Journal, 2008, 22, 3224-3233.	0.5	210
30	Up-Regulation of Inhibitors of Protein Phosphatase-2A in Alzheimer's Disease. American Journal of Pathology, 2005, 166, 1761-1771.	3.8	203
31	Alzheimer's disease, a multifactorial disorder seeking multitherapies. Alzheimer's and Dementia, 2010, 6, 420-424.	0.8	186
32	Phosphorylation of Tau at Thr212, Thr231, and Ser262 Combined Causes Neurodegeneration. Journal of Biological Chemistry, 2010, 285, 30851-30860.	3.4	177
33	Ï„ is phosphorylated by GSK-3 at several sites found in Alzheimer disease and its biological activity markedly inhibited only after it is prephosphorylated by A-kinase. FEBS Letters, 1998, 436, 28-34.	2.8	174
34	Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3Î². FEBS Letters, 2002, 530, 209-214.	2.8	174
35	Polymerization of hyperphosphorylated tau into filaments eliminates its inhibitory activity. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 8864-8869.	7.1	174
36	Tau Becomes a More Favorable Substrate for GSK-3 When It Is Prephosphorylated by PKA in Rat Brain. Journal of Biological Chemistry, 2004, 279, 50078-50088.	3.4	168

#	Article	IF	Citations
37	Brain glucose transporters, Oâ€GlcNAcylation and phosphorylation of tau in diabetes and Alzheimerâ€™s disease. Journal of Neurochemistry, 2009, 111, 242-249.	3.9	167
38	Role of protein phosphatase-2A and -1 in the regulation of GSK-3, cdk5 and cdc2 and the phosphorylation of tau in rat forebrain. FEBS Letters, 2000, 485, 87-93.	2.8	165
39	Localization of active forms of C-jun kinase (JNK) and p38 kinase in Alzheimer's disease brains at different stages of neurofibrillary degeneration. Journal of Alzheimer's Disease, 2001, 3, 41-48.	2.6	156
40	Restoration of biological activity of Alzheimer abnormally phosphorylated Ï„ by dephosphorylation with protein phosphatase-2A, â^'2B and â^'1. Molecular Brain Research, 1996, 38, 200-208.	2.3	152
41	Tau passive immunization inhibits not only tau but also AÎ² pathology. Alzheimer's Research and Therapy, 2017, 9, 1.	6.2	147
42	Levels of normal and abnormally phosphorylated tau in different cellular and regional compartments of Alzheimer disease and control brains. FEBS Letters, 1994, 351, 80-84.	2.8	146
43	Potentiation of GSK-3-catalyzed Alzheimer-like phosphorylation of human tau by cdk5. Molecular and Cellular Biochemistry, 1997, 167, 99-105.	3.1	144
44	Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers. Annals of Neurology, 2005, 58, 748-757.	5.3	144
45	PP2A Regulates Tau Phosphorylation Directly and also Indirectly via Activating GSK-3Î². Journal of Alzheimer's Disease, 2010, 19, 1221-1229.	2.6	143
46	Alzheimer paired helical filaments Restoration of the biological activity by dephosphorylation. FEBS Letters, 1994, 349, 104-108.	2.8	142
47	Disruption of microtubule network by Alzheimer abnormally hyperphosphorylated tau. Acta Neuropathologica, 2007, 113, 501-511.	7.7	140
48	Alzheimer's Disease Abnormally Phosphorylated Ï„ Is Dephosphorylated by Protein Phosphatase-2B (Calcineurin). Journal of Neurochemistry, 2002, 62, 803-806.	3.9	137
49	Increased Dosage of Dyrk1A Alters Alternative Splicing Factor (ASF)-regulated Alternative Splicing of Tau in Down Syndrome. Journal of Biological Chemistry, 2008, 283, 28660-28669.	3.4	136
50	Okadaic-Acid-Induced Inhibition of Protein Phosphatase 2A Produces Activation of Mitogen-Activated Protein Kinases ERK1/2, MEK1/2, and p70 S6, Similar to That in Alzheimer's Disease. American Journal of Pathology, 2003, 163, 845-858.	3.8	134
51	Interaction of Tau Isoforms with Alzheimer's Disease Abnormally Hyperphosphorylated Tau and in VitroPhosphorylation into the Disease-like Protein. Journal of Biological Chemistry, 2001, 276, 37967-37973.	3.4	131
52	Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. FEBS Letters, 2004, 566, 261-269.	2.8	131
53	Role of glycosylation in hyperphosphorylation of tau in Alzheimer's disease. FEBS Letters, 2002, 512, 101-106.	2.8	123
54	Trophic factors counteract elevated FGF-2-induced inhibition of adult neurogenesis. Neurobiology of Aging, 2007, 28, 1148-1162.	3.1	123

#	Article	IF	Citations
55	Downâ€regulation of cAMPâ€dependent protein kinase by overâ€activated calpain in Alzheimer disease brain. Journal of Neurochemistry, 2007, 103, 2462-2470.	3.9	123
56	Impaired brain glucose metabolism leads to Alzheimer neurofibrillary degeneration through a decrease in tau O-GlcNAcylation. Journal of Alzheimer's Disease, 2006, 9, 1-12.	2.6	120
57	Microtubule-associated polypeptides tau are altered in Alzheimer paired helical filaments. Molecular Brain Research, 1988, 4, 43-52.	2.3	119
58	Protein changes in senile dementia. Brain Research, 1974, 77, 337-343.	2.2	118
59	Hyperphosphorylation and accumulation of neurofilament proteins in Alzheimer disease brain and in okadaic acid-treated SY5Y cells. FEBS Letters, 2001, 507, 81-87.	2.8	116
60	PKA modulates GSK-3Î²- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners. FEBS Letters, 2006, 580, 6269-6274.	2.8	114
61	Hyperphosphorylation determines both the spread and the morphology ofÂtau pathology. Alzheimer's and Dementia, 2016, 12, 1066-1077.	0.8	112
62	Multifactorial Hypothesis and Multi-Targets for Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2018, 64, S107-S117.	2.6	112
63	The regulation of phosphorylation of Ï„ in SY5Y neuroblastoma cells: the role of protein phosphatases. FEBS Letters, 1998, 426, 248-254.	2.8	108
64	The dentate gyrus neurogenesis: a therapeutic target for Alzheimer's disease. Acta Neuropathologica, 2003, 105, 225-232.	7.7	108
65	Involvement of in the abnormal hyperphosphorylation of tau and its reversal by Memantine. FEBS Letters, 2006, 580, 3973-3979.	2.8	106
66	Dynamic Regulation of Expression and Phosphorylation of Tau by Fibroblast Growth Factor-2 In Neural Progenitor Cells from Adult Rat Hippocampus. Journal of Neuroscience, 1999, 19, 5245-5254.	3.6	102
67	Anesthesia Induces Phosphorylation of Tau. Journal of Alzheimer's Disease, 2009, 16, 619-626.	2.6	101
68	Activation of Asparaginyl Endopeptidase Leads to Tau Hyperphosphorylation in Alzheimer Disease. Journal of Biological Chemistry, 2013, 288, 17495-17507.	3.4	100
69	Cross talk between PI3K-AKT-GSK-3Î² and PP2A pathways determines tau hyperphosphorylation. Neurobiology of Aging, 2015, 36, 188-200.	3.1	99
70	Alzheimer disease therapeutics: Focus on the disease and not just plaques and tangles. Biochemical Pharmacology, 2014, 88, 631-639.	4.4	95
71	Mechanism of inhibition of PP2A activity and abnormal hyperphosphorylation of tau by I₂^{PP2A}/SET. FEBS Letters, 2011, 585, 2653-2659.	2.8	94
72	Intranasal insulin restores insulin signaling, increases synaptic proteins, and reduces Aβ2 level and microglia activation in the brains of 3xTg-AD mice. Experimental Neurology, 2014, 261, 610-619.	4.1	94

#	Article	IF	Citations
73	Pharmacologic reversal of neurogenic and neuroplastic abnormalities and cognitive impairments without affecting AÎ² and tau pathologies in 3xTg-AD mice. Acta Neuropathologica, 2010, 120, 605-621.	7.7	93
74	Dephosphorylation of microtubule-associated protein tau by protein phosphatase-1 and -2C and its implication in Alzheimer disease. FEBS Letters, 1994, 341, 94-98.	2.8	92
75	Role of tau phosphorylation by glycogen synthase kinase-3Î² in the regulation of organelle transport. Journal of Cell Science, 2004, 117, 1653-1663.	2.0	92
76	Metabolic/signal transduction hypothesis of Alzheimer?s disease and other tauopathies. Acta Neuropathologica, 2005, 109, 25-31.	7.7	89
77	Modulation of GSK-3-catalyzed phosphorylation of microtubule-associated protein tau by non-proline-dependent protein kinases. FEBS Letters, 1995, 358, 4-8.	2.8	87
78	Inhibition of PP-2A upregulates CaMKII in rat forebrain and induces hyperphosphorylation of tau at Ser 262/356. FEBS Letters, 2001, 490, 15-22.	2.8	87
79	Relevance of Phosphorylation and Truncation of Tau to the Etiopathogenesis of Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2018, 10, 27.	3.4	86
80	Intracerebroventricular Streptozotocin Exacerbates Alzheimer-Like Changes of 3xTg-AD Mice. Molecular Neurobiology, 2014, 49, 547-562.	4.0	85
81	Pathological Tau From Alzheimerâ€™s Brain Induces Site-Specific Hyperphosphorylation and SDS- and Reducing Agent-Resistant Aggregation of Tau in vivo. Frontiers in Aging Neuroscience, 2019, 11, 34.	3.4	85
82	Regulation of the alternative splicing of tau exon 10 by SC35 and Dyrk1A. Nucleic Acids Research, 2011, 39, 6161-6171.	14.5	84
83	Isolation of neurons and glial cells from normal and pathological human brains. Brain Research, 1972, 45, 296-301.	2.2	82
84	Targeting Tau Protein in AlzheimerÊ¼s Disease. Drugs and Aging, 2010, 27, 351-365.	2.7	82
85	Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimerâ€™s disease. Molecular Neurodegeneration, 2016, 11, 50.	10.8	82
86	Dual-specificity Tyrosine Phosphorylation-regulated Kinase 1A (Dyrk1A) Modulates Serine/Arginine-rich Protein 55 (SRp55)-promoted Tau Exon 10 Inclusion. Journal of Biological Chemistry, 2012, 287, 30497-30506.	3.4	81
87	Hyperphosphorylation-Induced Tau Oligomers. Frontiers in Neurology, 2013, 4, 112.	2.4	80
88	The carboxyâ€terminal fragment of inhibitorâ€2 of protein phosphataseâ€2A induces Alzheimer disease pathology and cognitive impairment. FASEB Journal, 2010, 24, 4420-4432.	0.5	79
89	Tau pathology involves protein phosphatase 2A in Parkinsonism-dementia of Guam. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 1144-1149.	7.1	79
90	Passive immunization targeting the N-terminal projection domain of tau decreases tau pathology and improves cognition in a transgenic mouse model of Alzheimer disease and tauopathies. Journal of Neural Transmission, 2015, 122, 607-617.	2.8	79

#	Article	IF	Citations
91	Oâ€GlcNAcylation: A regulator of tau pathology and neurodegeneration. Alzheimer's and Dementia, 2016, 12, 1078-1089.	0.8	79
92	Rapid Alzheimer-like phosphorylation of tau by the synergistic actions of non-proline-dependent protein kinases and GSK-3. FEBS Letters, 1995, 358, 267-272.	2.8	77
93	Cytosolic Abnormally Hyperphosphorylated Tau But Not Paired Helical Filaments Sequester Normal MAPs and Inhibit Microtubule Assembly. Journal of Alzheimer's Disease, 2008, 14, 365-370.	2.6	76
94	Enhancement of dentate gyrus neurogenesis, dendritic and synaptic plasticity and memory by a neurotrophic peptide. Neurobiology of Aging, 2011, 32, 1420-1434.	3.1	76
95	Cyclic AMP-dependent Protein Kinase Regulates the Alternative Splicing of Tau Exon 10. Journal of Biological Chemistry, 2011, 286, 14639-14648.	3.4	76
96	Differential Effects of an O-GlcNAcase Inhibitor on Tau Phosphorylation. PLoS ONE, 2012, 7, e35277.	2.5	76
97	Regulation of phosphorylation of neuronal microtubule-associated proteins MAP1b and MAP2 by protein phosphatase-2A and -2B in rat brain. Brain Research, 2000, 853, 299-309.	2.2	75
98	Early-Onset Network Hyperexcitability in Presymptomatic Alzheimerâ€™s Disease Transgenic Mice Is Suppressed by Passive Immunization with Anti-Human APP/Aî² Antibody and by mGluR5 Blockade. Frontiers in Aging Neuroscience, 2017, 9, 71.	3.4	75
99	Immunochemical Properties of Ubiquitin Conjugates in the Paired Helical Filaments of Alzheimer Disease. Journal of Neurochemistry, 1989, 52, 1523-1528.	3.9	73
100	Tau passive immunization blocks seeding and spread of Alzheimer hyperphosphorylated Tau-induced pathology in 3â€‰Ã—â€‰Tg-AD mice. Alzheimer's Research and Therapy, 2018, 10, 13.	6.2	73
101	Phosphorylation of Ï„ Protein by Casein Kinaseâ€1 Converts It to an Abnormal Alzheimerâ€Like State. Journal of Neurochemistry, 1995, 64, 1420-1423.	3.9	72
102	Inhibitors of protein phosphatase-2A from human brain structures, immunocytological localization and activities towards dephosphorylation of the Alzheimer type hyperphosphorylated tau. FEBS Letters, 2005, 579, 363-372.	2.8	72
103	Regulation between Oâ€GlcNAcylation and phosphorylation of neurofilamentâ€M and their dysregulation in Alzheimer disease. FASEB Journal, 2008, 22, 138-145.	0.5	72
104	An experimental rat model of sporadic Alzheimerâ€™s disease and rescue of cognitive impairment with a neurotrophic peptide. Acta Neuropathologica, 2012, 123, 133-151.	7.7	72
105	Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease. Neurobiology of Disease, 2014, 71, 110-130.	4.4	71
106	Blood-Cerebrospinal Fluid Barrier Permeability in Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 25, 505-515.	2.6	70
107	Calcium/calmodulin-dependent protein kinase II phosphorylates tau at Ser-262 but only partially inhibits its binding to microtubules. FEBS Letters, 1996, 387, 145-148.	2.8	69
108	I PP2A 1 Affects Tau Phosphorylation via Association with the Catalytic Subunit of Protein Phosphatase 2A. Journal of Biological Chemistry, 2008, 283, 10513-10521.	3.4	68

#	Article	IF	Citations
109	Dephosphorylation of microtubuleâ€associated protein tau by protein phosphatase 5. Journal of Neurochemistry, 2004, 88, 298-310.	3.9	66
110	Microtubule-associated protein tau as a therapeutic target in Alzheimer's disease. Expert Opinion on Therapeutic Targets, 2014, 18, 307-318.	3.4	65
111	Ser-262 in human recombinant tau protein is a markedly more favorable site for phosphorylation by CaMKII than PKA or PhK. FEBS Letters, 1998, 436, 471-475.	2.8	61
112	Cytoplasmic Retention of Protein Phosphatase 2A Inhibitor 2 (I2PP2A) Induces Alzheimer-like Abnormal Hyperphosphorylation of Tau. Journal of Biological Chemistry, 2014, 289, 27677-27691.	3.4	59
113	Alzheimer's disease neurofibrillary degeneration: pivotal and multifactorial. Biochemical Society Transactions, 2010, 38, 962-966.	3.4	58
114	Regulation of phosphorylation of tau by cyclin-dependent kinase 5 and glycogen synthase kinase-3 at substrate level. FEBS Letters, 2006, 580, 5925-5933.	2.8	56
115	Dysregulation of Protein Phosphorylation/Dephosphorylation in Alzheimer's Disease: A Therapeutic Target. Journal of Biomedicine and Biotechnology, 2006, 2006, 1-11.	3.0	56
116	Comparison of the phosphorylation of microtubule-associated protein tau by non-proline dependent protein kinases. Molecular and Cellular Biochemistry, 1994, 131, 181-189.	3.1	55
117	Inhibition of protein phosphatase 2A induces phosphorylation and accumulation of neurofilaments in metabolically active rat brain slices. Neuroscience Letters, 2003, 340, 107-110.	2.1	54
118	Neurogenic and Neurotrophic Effects of BDNF Peptides in Mouse Hippocampal Primary Neuronal Cell Cultures. PLoS ONE, 2013, 8, e53596.	2.5	54
119	Truncation of Tau selectively facilitates its pathological activities. Journal of Biological Chemistry, 2020, 295, 13812-13828.	3.4	54
120	Insulin sensitizers improve learning and attenuate tau hyperphosphorylation and neuroinflammation in 3xTg-AD mice. Journal of Neural Transmission, 2015, 122, 593-606.	2.8	53
121	Beneficial Effect of a CNTF Tetrapeptide on Adult Hippocampal Neurogenesis, Neuronal Plasticity, and Spatial Memory in Mice. Journal of Alzheimer's Disease, 2010, 21, 1185-1195.	2.6	51
122	Truncation and Activation of Dual Specificity Tyrosine Phosphorylation-regulated Kinase 1A by Calpain I. Journal of Biological Chemistry, 2015, 290, 15219-15237.	3.4	51
123	Cerebrospinal Fluid Secretory Ca2+-Dependent Phospholipase A2 Activity Is Increased in Alzheimer Disease. Clinical Chemistry, 2009, 55, 2171-2179.	3.2	48
124	Opportunities and challenges in developing Alzheimer disease therapeutics. Acta Neuropathologica, 2011, 122, 543-549.	7.7	47
125	Brain Gene Expression of a Sporadic (icv-STZ Mouse) and a Familial Mouse Model (3xTg-AD Mouse) of Alzheimerâ€™s Disease. PLoS ONE, 2012, 7, e51432.	2.5	47
126	Therapeutic benefits of a component of coffee in a rat model of Alzheimer's disease. Neurobiology of Aging, 2014, 35, 2701-2712.	3.1	46

#	Article	IF	Citations
127	Rescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound. Neurobiology of Aging, 2014, 35, 2134-2146.	3.1	45
128	Neurotrophic peptides incorporating adamantane improve learning and memory, promote neurogenesis and synaptic plasticity in mice. FEBS Letters, 2010, 584, 3359-3365.	2.8	44
129	Inhibition of protein phosphatase-2B (calcineurin) activity towards Alzheimer abnormally phosphorylated Ï„ by neuroleptics. Brain Research, 1996, 741, 95-102.	2.2	43
130	Intranasal insulin prevents anesthesia-induced hyperphosphorylation of tau in 3xTg-AD mice. Frontiers in Aging Neuroscience, 2014, 6, 100.	3.4	41
131	Expression of Tau Pathology-Related Proteins in Different Brain Regions: A Molecular Basis of Tau Pathogenesis. Frontiers in Aging Neuroscience, 2017, 9, 311.	3.4	40
132	Decrease of Protein Phosphatase 2A and its Association with Accumulation and Hyperphosphorylation of Tau in Down Syndrome. Journal of Alzheimer's Disease, 2008, 13, 295-302.	2.6	39
133	Regulation of Phosphorylation of tau by Protein Kinases in Rat Brain. Neurochemical Research, 2006, 31, 1473-1480.	3.3	37
134	Recent developments with tau-based drug discovery. Expert Opinion on Drug Discovery, 2018, 13, 399-410.	5.0	35
135	Alzheimerâ€™s disease brain contains tau fractions with differential prion-like activities. Acta Neuropathologica Communications, 2021, 9, 28.	5.2	35
136	A Novel Therapeutic Approach to Treat Alzheimerâ€™s Disease by Neurotrophic Support During the Period of Synaptic Compensation. Journal of Alzheimer's Disease, 2018, 62, 1211-1218.	2.6	33
137	Mechanism of Tau Hyperphosphorylation Involving Lysosomal Enzyme Asparagine Endopeptidase in a Mouse Model of Brain Ischemia. Journal of Alzheimer's Disease, 2018, 63, 821-833.	2.6	33
138	Cerebrospinal fluid secretory Ca2+-dependent phospholipase A2 activity: A biomarker of bloodâ€“cerebrospinal fluid barrier permeability. Neuroscience Letters, 2010, 478, 179-183.	2.1	30
139	Pathological Alterations of Tau in Alzheimerâ€™s Disease and 3xTg-AD Mouse Brains. Molecular Neurobiology, 2019, 56, 6168-6183.	4.0	29
140	Rescue of Synaptic Failure and Alleviation of Learning and Memory Impairments in a Trisomic Mouse Model of Down Syndrome. Journal of Neuropathology and Experimental Neurology, 2011, 70, 1070-1079.	1.7	28
141	O-GlcNAc cycling modulates neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 17319-17320.	7.1	27
142	Animal Models of the Sporadic Form of Alzheimer's Disease: Focus on the Disease and Not Just the Lesions1. Journal of Alzheimer's Disease, 2013, 37, 469-474.	2.6	27
143	Young blood plasma reduces Alzheimerâ€™s disease-like brain pathologies and ameliorates cognitive impairment in 3Ã—Tg-AD mice. Alzheimer's Research and Therapy, 2020, 12, 70.	6.2	27
144	Alzheimer disease and amyotrophic lateral sclerosis: an etiopathogenic connection. Acta Neuropathologica, 2014, 127, 243-256.	7.7	26

#	Article	IF	Citations
145	Enhancement of Neurogenesis and Memory by a Neurotrophic Peptide in Mild to Moderate Traumatic Brain Injury. Neurosurgery, 2015, 76, 201-215.	1.1	26
146	Multi-Targets: An Unconventional Drug Development Strategy for Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2022, 14, 837649.	3.4	26
147	A pool of Î²-tubulin is hyperphosphorylated at serine residues in Alzheimer disease brain. FEBS Letters, 2001, 509, 375-381.	2.8	25
148	Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound. Alzheimer's Research and Therapy, 2017, 9, 45.	6.2	25
149	GSK-3Î² is Dephosphorylated by PP2A in a Leu309 Methylation-Independent Manner. Journal of Alzheimer's Disease, 2015, 49, 365-375.	2.6	24
150	Guanosine Triphosphate Binding to Î²-Subunit of Tubulin in Alzheimer's Disease Brain: Role of Microtubule-Associated Protein Ì„. Journal of Neurochemistry, 2002, 64, 777-787.	3.9	23
151	Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimerâ€™s-like memory deficits in the Ts65Dn mouse model of Down syndrome. Scientific Reports, 2017, 7, 45561.	3.3	23
152	Inhibitors of protein phosphatase-2A: topography and subcellular localization. Molecular Brain Research, 2004, 126, 146-156.	2.3	21
153	Synaptic Compensation as a Probable Cause of Prolonged Mild Cognitive Impairment in Alzheimerâ€™s Disease: Implications from a Transgenic Mouse Model of the Disease. Journal of Alzheimer's Disease, 2017, 56, 1385-1401.	2.6	21
154	Involvement of Activation of Asparaginyl Endopeptidase in Tau Hyperphosphorylation in Repetitive Mild Traumatic Brain Injury. Journal of Alzheimer's Disease, 2018, 64, 709-722.	2.6	20
155	Memantine Attenuates Alzheimerâ€™s Disease-Like Pathology and Cognitive Impairment. PLoS ONE, 2015, 10, e0145441.	2.5	20
156	Regional Comparison of the Neurogenic Effects of CNTF-Derived Peptides and Cerebrolysin in AÎ²PP Transgenic Mice. Journal of Alzheimer's Disease, 2011, 27, 743-752.	2.6	19
157	Inhibition of Protein Phosphatase-2A (PP2A) by I1PP2A Leads to Hyperphosphorylation of Tau, Neurodegeneration, and Cognitive Impairment in Rats. Journal of Alzheimer's Disease, 2015, 45, 423-435.	2.6	19
158	Sera from Children with Autism Induce Autistic Features Which Can Be Rescued with a CNTF Small Peptide Mimetic in Rats. PLoS ONE, 2015, 10, e0118627.	2.5	18
159	Prevention of Amyloid-Î² and Tau Pathologies, Associated Neurodegeneration, and Cognitive Deficit by Early Treatment with a Neurotrophic Compound. Journal of Alzheimer's Disease, 2017, 58, 215-230.	2.6	18
160	Role of Ciliary Neurotrophic Factor in the Proliferation and Differentiation of Neural Stem Cells. Journal of Alzheimer's Disease, 2013, 37, 587-592.	2.6	17
161	Shifting balance from neurodegeneration to regeneration of the brain: a novel therapeutic approach to Alzheimerâ€²s disease and related neurodegenerative conditions. Neural Regeneration Research, 2014, 9, 1518.	3.0	17
162	Multiple forms of phosphatase from human brain: isolation and partial characterization of affi-gel blue binding phosphatases. Neurochemical Research, 2000, 25, 107-120.	3.3	15

#	Article	IF	Citations
163	Elevated Tau Level in Aged Rat Cerebrospinal Fluid Reduced by Treatment with a Neurotrophic Compound. Journal of Alzheimer's Disease, 2015, 47, 557-564.	2.6	15
164	Neonatal Exposure to Anesthesia Leads to Cognitive Deficits in Old Age: Prevention with Intranasal Administration of Insulin in Mice. Neurotoxicity Research, 2020, 38, 299-311.	2.7	15
165	Multiple forms of phosphatase from human brain: isolation and partial characterization of affi-gel blue nonbinding phosphatase activities. Neurochemical Research, 2001, 26, 425-438.	3.3	12
166	Inhibition of AMD-Like Pathology With a Neurotrophic Compound in Aged Rats and 3xTg-AD Mice. Frontiers in Aging Neuroscience, 2019, 11, 309.	3.4	10
167	Neurotrophic Treatment Initiated During Early Postnatal Development Prevents the Alzheimer-Like Behavior and Synaptic Dysfunction. Journal of Alzheimer's Disease, 2021, 82, 631-646.	2.6	10
168	Stratification of Patients is the Way to Go to Develop Neuroprotective/Disease-Modifying Drugs for Alzheimer's Disease. Journal of Alzheimer's Disease, 2008, 15, 339-345.	2.6	9
169	Elevation of casein kinase 1Îµ associated with TDPâ€43 and tau pathologies in Alzheimer's disease. Brain Pathology, 2020, 30, 283-297.	4.1	9
170	Subacute to chronic Alzheimer-like alterations after controlled cortical impact in human tau transgenic mice. Scientific Reports, 2019, 9, 3789.	3.3	8
171	Alzheimer's disease research in Ibero America. Alzheimer's and Dementia, 2016, 12, 749-754.	0.8	7
172	Prenatal to early postnatal neurotrophic treatment prevents Alzheimer-like behavior and pathology in mice. Alzheimer's Research and Therapy, 2020, 12, 102.	6.2	7
173	Thiamme2-G, a Novel O-GlcNAcase Inhibitor, Reduces Tau Hyperphosphorylation and Rescues Cognitive Impairment in Mice. Journal of Alzheimer's Disease, 2021, 81, 273-286.	2.6	5
174	Seeding-Competent Tau in Gray Matter Versus White Matter of Alzheimerâ€™s Disease Brain. Journal of Alzheimer's Disease, 2021, 79, 1647-1659.	2.6	4
175	Thinking beyond the Aducanumab Controversy. Annals of Neurology, 2021, 90, 1003-1004.	5.3	4
176	Heightened Tameness and Accelerated Handling-Habituation in 3Ã—Tg-AD Mice on a B6;129 Genetic Background. Journal of Alzheimer's Disease Reports, 2022, 6, 245-255.	2.2	4
177	O2-06-04: A NOVEL PHARMACOLOGIC THERAPEUTIC APPROACH TO ALZHEIMER DISEASE AND COGNITIVE AGING. , 2014, 10, P175-P175.		1
178	Rats Display Sexual Dimorphism in Phosphorylation of Brain Tau with Age. Journal of Alzheimer's Disease, 2021, 82, 855-869.	2.6	1
179	Does proteopathic tau propagate trans-synaptically in the brain?. Molecular Neurodegeneration, 2022, 17, 21.	10.8	1
180	O3-04-05: Rescue of pathology and cognitive impairment by tau immunotherapy at a moderate to severe stage of the disease in 3xTg-alzheimer's disease mice. , 2015, 11, P227-P227.		0

#	Article	IF	Citations
181	O4-04-03: Molecular Mechanism of Tau Spread and Tau Sites to Target for Immunotherapy. , 2016, 12, P340-P341.		0
182	[F3â€“07â€“02]: TAU IMMUNOTHERAPY PREVENTS THE SPREAD AND PROMOTES THE CLEARANCE OF PATHOLOGY IN MICE. Alzheimer's and Dementia, 2017, 13, P888.	0.8	0
183	[P2â€“169]: ALZHEIMER's DISEASE IN DOWN SYNDROME CAN BE PREVENTED BY PHARMACOLOGIC TREATMENT DURING PRENATAL TO EARLY POSTNATAL DEVELOPMENT. Alzheimer's and Dementia, 2017, 13, P671.	0.8	0
184	P3â€055: RESCUE OF NEUROTROPHIC DEFICIT DURING PRENATAL TO EARLY POSTNATAL DEVELOPMENT CAN PREVENT ALZHEIMERâ€LIKE COGNITIVE IMPAIRMENT LATER IN LIFE. Alzheimer's and Dementia, 2018, 14, P1085.	0.8	0
185	Why delay in effective treatment for Alzheimer's disease and related conditions. Progress in Molecular Biology and Translational Science, 2019, 168, 243-256.	1.7	0
186	Tau immunotherapy rescues cognitive impairment by clearing extracellular tau. Alzheimer's and Dementia, 2020, 16, e037315.	0.8	0